Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Analysts Predict Sanofi Surge Past Pfizer

November 3, 2011 6:41 am | News | Comments

After nine years as the world’s biggest maker of medicines, Pfizer is set to cede its crown next year to a company that a decade ago few would have predicted to be leading the pharma league tables – Sanofi.

TOPICS:

Pluristem Announces Positive PLX-PAD Data

November 3, 2011 6:32 am | News | Comments

PLX-PAD cells from Pluristem Therapeutics, Inc. met all the clinical studies’ protocol endpoints, demonstrating a safe immunologic profile at all dosage levels and found to be potentially effective in treating patients suffering from critical limb ischemia.

TOPICS:

FDA Grants Lupuzor Fast Track Status

November 3, 2011 6:24 am | News | Comments

Following ImmuPharma’s Investigational New Drug filing with the FDA and the successful completion of a Phase 2b study, the FDA has granted Lupuzor Fast Track designation.

TOPICS:
Advertisement

FDA Panel Backs Expanded Vytorin Use

November 3, 2011 6:18 am | News | Comments

Federal health experts are recommending that use of Merck's blockbuster cholesterol drug Vytorin be expanded to patients with kidney disease, but not those with late-stage disease who are on dialysis.

TOPICS:

P & G Combining Medical Unit with Teva

November 3, 2011 6:16 am | by Christina Rexrode | News | Comments

Procter & Gamble Co. said that it has combined some of its drug units with Jerusalem-based Teva Pharmaceutical Industries Ltd., a move that should help the companies expand in China and other emerging markets.

TOPICS:

GSK Agrees to $3B Settlement Deal

November 3, 2011 6:12 am | News | Comments

Drug maker GlaxoSmithKline PLC said that it has agreed in principle with the United States government on a $3 billion settlement of investigations of the company's sales and marketing practices.

TOPICS:

Lilly CEO Wants Benefits/Risk Assessments

November 2, 2011 12:54 pm | News | Comments

To sustain medical innovation, the U.S. Food and Drug Administration must accelerate the adoption of a benefit-risk framework to inform decision-making in the regulatory process.

TOPICS:

Regulus Therapeutics Gains Additional Patent Coverage

November 2, 2011 12:31 pm | News | Comments

Regulus Therapeutics Inc. announced that the Australian Patent Office has granted claims in the ‘Sarnow’ patent series for microRNA-122 therapy in the treatment of hepatitis C viral infections.

Advertisement

Study Shows How H.plylori Causes Cell Death

November 2, 2011 12:14 pm | News | Comments

Researchers have figured out how Helicobacter pylori attacks a cell’s energy infrastructure, sparking a series of events in the cell that ultimately lead it to self-destruct.

Ebola, Marburg Virus Treatments Safe in Phase 1 Studies

November 2, 2011 12:06 pm | News | Comments

AVI BioPharma Inc. announced positive safety results from the first five cohorts of Phase 1 single ascending dose trials of AVI-6002 and AVI-6003.

Gilead Gains Positive Feedback on HIV Drug

November 2, 2011 12:01 pm | News | Comments

The Committee for Medicinal Products for Human Use adopted a positive opinion on the Gilead Sciences Inc ‘s marketing authorization application for the once-daily single-tablet regimen, Eviplera.

Genticel Completes ProCervix Trial Recruitment

November 2, 2011 11:54 am | News | Comments

Genticel has completed the recruitment of patients participating in its Phase 1 clinical trial with a liquid formulation of ProCervix.

Bioisostere Replacement Software

November 2, 2011 7:42 am | Product Releases | Comments

Cresset has released its latest version of the bioisostere replacement tool, FieldStere. FieldStere uses Cresset’s field-point technology, together with a database of molecular fragments, to help guide drug discovery projects.

TOPICS:

Piezo-assisted Micromanipulation

November 2, 2011 7:27 am | Product Releases | Comments

The PiezoXpert from Eppendorf is designed for piezo-assisted microinjection or manipulation techniques. Digital programmable parameter setting allows the user to perforate cell membranes with the utmost accuracy and reproducibility.

TOPICS:

Selventa Working with Linguamatics

November 2, 2011 7:13 am | News | Comments

Selventa, a personalized healthcare company, has formed a strategic scientific alliance with Linguamatics, a software solutions company that provides knowledge extraction through its I2E natural language processing text mining platform.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading